LAVA Therapeutics (LVTX) Stock Price, News & Analysis

Company Overview

LAVA Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of next-generation cancer immunotherapies. The company’s proprietary platform leverages the unique biology of gamma delta (γδ) T cells—immune cells that combine innate and adaptive functions—to create bispecific and multispecific antibodies designed to recruit and activate γδ T cells against a broad range of solid tumors and hematological malignancies.

At the core of LAVA’s pipeline is its Gammabody® platform, which engineers antibodies to precisely engage γδ T cell receptors in conjunction with tumor-associated antigens. Lead candidates include LAVA-051, a first-in-class bispecific targeting Vγ9Vδ2 T cells and CD1d for the treatment of hematological cancers, and LAVA-1207, which recruits Vγ9Vδ2 T cells to prostate-specific membrane antigen (PSMA) in prostate cancer. Additional preclinical programs aim to expand the technology to other solid tumor indications and novel tumor-specific targets.

Founded in 2016 and headquartered in Amsterdam with a research and clinical development presence in Boston, Massachusetts, LAVA has built a multidisciplinary team comprising immunologists, antibody engineers and clinical development experts. The company completed its initial public offering on the Nasdaq in 2021. Under the leadership of Chief Executive Officer J.P. Castaigne and Chief Scientific Officer Andreas Hofmann, LAVA continues to advance its portfolio through regulatory filings and early-stage clinical trials across Europe and North America.

Key Stats

• Today's Range: $1.39 to $1.43
• 50-Day Range: $1.23 to $1.48
• 52-Week Range: $0.85 to $2.39
• Volume: 15,931 shs
• Average Volume: 152,644 shs
• Market Capitalization: $37.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.17
• Consensus Rating: Hold

LAVA Therapeutics Stock Analysis - MarketRank™

LAVA Therapeutics scored higher than 44% of companies evaluated by MarketBeat, and ranked 652nd out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

LAVA Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.

Amount of Analyst Coverage

LAVA Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for LAVA Therapeutics are expected to decrease in the coming year, from ($1.13) to ($1.30) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of LAVA Therapeutics is -1.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of LAVA Therapeutics is -1.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

LAVA Therapeutics has a P/B Ratio of 1.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.44% of the float of LAVA Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

LAVA Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in LAVA Therapeutics has recently decreased by 10.53%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

LAVA Therapeutics does not currently pay a dividend.

Dividend Growth

LAVA Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.44% of the float of LAVA Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

LAVA Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in LAVA Therapeutics has recently decreased by 10.53%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

LAVA Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.97 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for LAVA Therapeutics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, LAVA Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.50% of the stock of LAVA Therapeutics is held by insiders.

LVTX Stock Analysis - Frequently Asked Questions

How have LVTX shares performed this year?

LAVA Therapeutics' stock was trading at $0.9510 at the beginning of 2025. Since then, LVTX stock has increased by 50.4% and is now trading at $1.43.

How were LAVA Therapeutics' earnings last quarter?

LAVA Therapeutics N.V. (NASDAQ:LVTX) released its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.24.

When did LAVA Therapeutics IPO?

LAVA Therapeutics (LVTX) raised $100 million in an initial public offering on Thursday, March 25th 2021. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and SVB Leerink served as the underwriters for the IPO and Kempen & Co. was co-manager.

How do I buy shares of LAVA Therapeutics?

Shares of LVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of LAVA Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that LAVA Therapeutics investors own include Broadcom (AVGO), NVIDIA (NVDA), Adobe (ADBE), Arista Networks (ANET), New Oriental Education & Technology Group (EDU), ServiceNow (NOW) and AppLovin (APP).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/16/2025
• Next Earnings (Estimated): 8/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LVTX
• CIK: 1840748
• Web: www.lavatherapeutics.com
• Phone: 31-85-016-3100
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Price Target for LAVA Therapeutics: $3.17
• High Price Target: $6.00
• Low Price Target: $1.50
• Potential Upside/Downside: +121.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$25.11 million
• Net Margins: N/A
• Pretax Margin: -545.07%
• Return on Equity: -86.38%
• Return on Assets: -34.12%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.73
• Quick Ratio: 6.73

Sales & Book Value

• Annual Sales: $11.98 million
• Price / Sales: 3.14
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.06 per share
• Price / Book: 1.35

Miscellaneous

• Outstanding Shares: 26,310,000
• Free Float: 23,806,000
• Market Cap: $37.62 million
• Optionable: Optionable
• Beta: 0.48